{"id":"dolutegravir-film-coated-dispersible-tablets","safety":{"commonSideEffects":[{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL4303416","moleculeType":"Small molecule","molecularWeight":"419.38"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dolutegravir is an integrase strand transfer inhibitor (INSTI) that binds to HIV integrase and blocks the enzyme's ability to catalyze the integration of viral DNA into the human genome. By preventing integration, the drug stops HIV replication at a critical step in the viral lifecycle. This mechanism is effective against both treatment-naive and treatment-experienced patients, including those with certain integrase inhibitor-resistant strains.","oneSentence":"Dolutegravir inhibits HIV integrase, preventing the virus from integrating its genetic material into the host cell's DNA.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:09:44.171Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naive adults and children"},{"name":"HIV-1 infection in treatment-experienced patients"}]},"trialDetails":[{"nctId":"NCT05993767","phase":"PHASE2","title":"UNIVERSAL 1: Pharmacokinetic Study of a Novel DTG/FTC/TAF Dose Ratio for Children","status":"COMPLETED","sponsor":"PENTA Foundation","startDate":"2024-12-11","conditions":"HIV Infection","enrollment":53},{"nctId":"NCT04337450","phase":"PHASE2, PHASE3","title":"DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children With HIV Infection Aged 2 to <15 Years Old","status":"ACTIVE_NOT_RECRUITING","sponsor":"PENTA Foundation","startDate":"2022-04-22","conditions":"HIV Infections","enrollment":386},{"nctId":"NCT03016533","phase":"PHASE3","title":"Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2017-06-06","conditions":"HIV Infections","enrollment":100},{"nctId":"NCT01302847","phase":"PHASE1, PHASE2","title":"Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-04-20","conditions":"HIV Infections","enrollment":181},{"nctId":"NCT02893488","phase":"PHASE1","title":"Relative Bioavailability Study of a Fixed-dose Combination Dolutegravir/Abacavir/Lamivudine Dispersible Tablet","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2016-09-01","conditions":"Infection, Human Immunodeficiency Virus","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Dolutegravir film-coated dispersible tablets","genericName":"Dolutegravir film-coated dispersible tablets","companyName":"ViiV Healthcare","companyId":"viiv-healthcare","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dolutegravir inhibits HIV integrase, preventing the virus from integrating its genetic material into the host cell's DNA. Used for HIV-1 infection in treatment-naive adults and children, HIV-1 infection in treatment-experienced patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}